RxDoctor Payments DataLook up a doctor →

Clark Griffith, MD

Obstetrics & Gynecology · Dallas, TXNPI 1588666242

Payments from drug & device makers

$1,297,266in general payments, 2019–2025

Across 896 payments — averaging $1447.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$804K
  • AbbVie$406K
  • Myovant Sciences GmbH$72K
  • Myovant Sciences Inc.$13K
  • Ascend Therapeutics US, LLC$366
  • Astellas Pharma US Inc$289
  • plus $2K from 29 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$2,77190%
  • Education$2588%
  • Gifts$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,297,266 in reported general payments places this provider in the 95th percentile of 3,099 obstetrics & gynecology providers in Texas.

See all obstetrics & gynecology providers in Texas

Medicare billing

Part B allowed, 2024
$25,455
Medicare patients
149
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron12$6,153
Estradiol87$5,209
Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet30$1,731
Raloxifene Hcl28$1,252
Estradiol (Twice Weekly)Estradiol15$1,226
ValacyclovirValacyclovir Hcl24$1,106
SynthroidLevothyroxine Sodium17$633
Clobetasol Propionate19$385
ProgesteroneProgesterone, Micronized13$312
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst13$153
Levothyroxine Sodium38$116
Fluconazole16$79
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid12$59
Alprazolam17$25
Fluoxetine Hcl20$25

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$289$6,15312 claims
AbbVieSynthroid$405,938$63317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,099 obstetrics & gynecology providers in Texas.

Other obstetrics & gynecology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →